Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.
The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to major depressive disorder.
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Update
Dr Steven Gourlay
CEO and MD
Michael Roberts
Head of investor relations
Forecast net debt (A$m)
1.9
Forecast gearing ratio (%)
27
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 18.8 | 31.0 | (38.2) |
Relative | 22.1 | 30.7 | (41.5) |
52 week high/low | A$0.1/A$0.0 |
Actinogen Medical’s lead asset, Xanamem, is a once-daily oral selective 11beta-HSD1 inhibitor, designed to cross the blood brain barrier and target excess brain cortisol, which has been associated with CI. The company is targeting two CI indications: for patients with mild CI in the early stages of Alzheimer’s disease (AD) and for patients with major depressive disorder. Positive clinical results in healthy adults demonstrated the drug’s initial efficacy, while an analysis of biomarker-positive patients using plasma samples from the previous XanADu study in mild AD also showed clinical activity. Actinogen dosed the first patient in its Phase IIb XanaMIA trial in patients with biomarker-confirmed early AD in April 2024, and plans to report interim data in mid CY25. It started the XanaCIDD proof-of-concept Phase II trial in major depressive disorder in Q4 CY22 and expects to report top-line data in early Q3 CY24.
Y/E Jun | Revenue (A$m) | EBITDA (A$m) | PBT (A$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 3.6 | (9.1) | (7.9) | (0.460) | N/A | N/A |
2023A | 4.9 | (10.6) | (8.9) | (0.494) | N/A | N/A |
2024E | 7.7 | (16.5) | (15.8) | (0.763) | N/A | N/A |
2025E | 20.3 | (35.2) | (37.9) | (1.628) | N/A | N/A |